Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00415818 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: MVA-MUC1-IL2
DRUG: 1st line Chemotherapy

Sponsor

Transgene